glp-1 manufacturing news today Compounded GLP-1s are entering a new phase of scrutiny. With the FDA targeting large-scale compounded manufacturing, patients are facing a moment where access, safety, and regulatory clarity all matter. In my GLP-1 agonist clinical pipeline 2026:

Nature website

Branched-chain acyl-CoA can be further metabolized in several steps to the TCA cycle, and intermediates, such as acetyl-CoA and/or succinyl-CoA, can be used for energy production (She et al., 2007) or acetylation modification (Campbell and Wellen, 2018)

As research continues to evolve, its essential for clinicians to stay informed on how to use these medications safely, effectively, and responsiblyincluding how to differentiate between agents, manage side effects, and individualize treatment plans

I said, "No, you have problem, let me help you get rid of the problem." And that's a whole different mentality